insertable loop recorder

insertable loop recorder

Cardiology An implantable Pt-activated monitoring system that records subcutaneous EKGs in Pts with Sx suggestive of arrhythmia. See Holter monitoring.
Mentioned in ?
References in periodicals archive ?
In a study of twenty-three patients with moderate to severe OSA who were each implanted with an insertable loop recorder, about 50% were observed to have frequent episodes of bradycardia and long pauses (complete heart block or sinus arrest) during sleep (9).
Severe bradyarrhythmias in patients with sleep apnoe: the effect of continuous positive airway pressure treatment: a long term evaluation using an insertable loop recorder // Eur.
Syncope Etiology Testing: Diagnostic Yield in Literature Test/Procedure Yield * History and physical (including carotid sinus massage) 49%-85% ECG 2%-11% Electrophysiology study (without structural heart disease) 11% Electrophysiology study (with structural heart disease) 49% Tilt table test (without structural heart disease) 11%-87% Ambulatory ECG monitors: Holter 2% External loop recorder (2-3 weeks' duration) 20% Insertable loop recorder (up to 14 months' duration) 65%-88% Neurologic work-up (head CT, carotid Doppler) 0%-4% * Based on average time to diagnosis of 5.
In practice, nurses now may more often encounter a patient who has had or will have implanted an insertable loop recorder (ILR), Reveal Plus[R].
Syncope Etiology Testing: Diagnostic Yield in Literature Test/Procedure Yield* History and physical (including carotid sinus massage) 49%-85% ECG 2%-11% Electrophysiology study (without structural heart disease) 11% Electrophysiology study (with structural heart disease) 49% Tilt table test (without structural heart disease) 11%-87% Ambulatory ECG monitors: Holter 2% External loop recorder (2-3 weeks' duration) 20% Insertable loop recorder (up to 14 months' duration 65%-88% Neurologic work-up (head CT, carotid Doppler) 0%-4% *Based on average time to diagnosis of 5.
A study published in a recent issue of the journal Circulation shows that patients who experience recurrent unexplained syncope (fainting) have a greater chance of being diagnosed if physicians use a Reveal Insertable Loop Recorder (ILR).
Devices such as the Medtronic Reveal[R] Plus insertable loop recorder (ILR) and Reveal[R] DX, the company's newest insertable cardiac monitor (ICM), can monitor asymptomatic arrhythmias and can be appropriate patient management tools for assessing post-MI patients who may benefit from drug or device (pacemaker or ICD) therapy.
Presented today as a Poster Session, CARISMA documented the incidence of cardiac arrhythmias using the Medtronic Reveal[R] Plus insertable loop recorder (ILR) and demonstrated the utility of heart rate variability parameters as appropriate risk stratifier for post-MI patients.
The strategy includes a simple initial evaluation, early use of the Medtronic Reveal(R) Plus insertable loop recorder (ILR), assessment of the exact mechanism of syncope and prescription of a mechanism-based therapy.
Among the many Medtronic activities planned, attendees will hear major scientific presentations about the Endeavor(TM) drug-eluting coronary stent programme, the CARE-HF heart failure trial, and the Reveal(R) Plus insertable loop recorder (ILR).
Our research shows that the Medtronic Reveal(R) Insertable Loop Recorder is both a cost-effective and quality diagnostic tool for many patients.
It covers multiple disease states, including bradycardia, tachycardia, heart failure and atrial fibrillation, as well as diagnostic devices such as the Reveal(R) Plus Insertable Loop Recorder and all Vitatron implantable cardiac devices.